Parlati Lucia, Régnier Marion, Guillou Hervé, Postic Catherine
Université de Paris, Institut Cochin, CNRS, INSERM, F- 75014 Paris, France.
Hôpital Cochin, 24, rue du Faubourg Saint Jacques, 75014 Paris, France.
JHEP Rep. 2021 Aug 8;3(6):100346. doi: 10.1016/j.jhepr.2021.100346. eCollection 2021 Dec.
Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide. It is characterised by steatosis, liver inflammation, hepatocellular injury and progressive fibrosis. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD. In this review, we will provide an update on the known molecular pathways involved in the pathophysiology of NAFLD and on ongoing studies of new therapeutic targets.
非酒精性脂肪性肝病（NAFLD）是全球慢性肝病日益增多的一个病因。其特征为脂肪变性、肝脏炎症、肝细胞损伤和进行性纤维化。NAFLD的几种临床前模型（饮食和基因动物模型）加深了我们对其病因学和病理生理学的理解。尽管取得了进展，但目前尚无针对NAFLD的有效治疗方法。在本综述中，我们将提供有关NAFLD病理生理学中已知分子途径以及新治疗靶点正在进行的研究的最新信息。
